Nabsys: Funding, Investors & Team (Sep 2026)
Using specialized electronic nano-channel detectors, Nabsys analyzes lengthy DNA molecules quickly. Nabsys is able to produce a resolution that is substantially higher than what is possible using optical mapping techniques. Whole genome maps are created by Nabsys HD-MappingTM solid-state electronic nano-channel detectors at sub-diffraction-limit resolution. These maps provide significant benefits for assembling genomes, analyzing structural variation, and verifying putative variants identified by other technologies. Long DNA molecules are given sequence-specific tags via HD-Mapping. These molecules are controlled via electrophoretic and hydrodynamic control to go through the nano-detectors at high speed. The detectors provide information about where the molecules' sequence-specific tags are located. After that, Nabsys analytical software analyzes the data.
Nabsys has raised $38.0M across 2 funding rounds on record, the most recent an undisclosed round of $13.0M announced in Nov 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Nabsys Company Profile and Key Stats
Latest funding round on record: Nov 2022.
Nabsys Funding Rounds
Nabsys raised $25.0M in a Corporate Round announced in Apr 2022.
7 months later, an undisclosed round of $13.0M was announced in Nov 2022.
Nabsys Founders and Leadership Team
Contact details for the Nabsys team: 1 of 1 has an email address on file.
Start 14-day free trial →Nabsys Funding Compared to Other Biotechnology Startups
Nabsys' latest round of $13.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Nabsys in Biotechnology and Providence
Companies Similar to Nabsys
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Nabsys Funding FAQs
What does Nabsys do?
Using specialized electronic nano-channel detectors, Nabsys analyzes lengthy DNA molecules quickly. Nabsys is able to produce a resolution that is substantially higher than what is possible using optical mapping techniques. Whole genome maps are created by Nabsys HD-MappingTM solid-state electronic nano-channel detectors at sub-diffraction-limit resolution. These maps provide significant benefits for assembling genomes, analyzing structural variation, and verifying putative variants identified by other technologies. Long DNA molecules are given sequence-specific tags via HD-Mapping. These molecules are controlled via electrophoretic and hydrodynamic control to go through the nano-detectors at high speed. The detectors provide information about where the molecules' sequence-specific tags are located. After that, Nabsys analytical software analyzes the data.
How much funding has Nabsys raised?
Nabsys has raised $38.0M across 2 rounds on record. The most recent is an undisclosed round of $13.0M announced in Nov 2022.
When did Nabsys last raise funding?
Nabsys' most recent funding round on record is an undisclosed round of $13.0M, announced in Nov 2022.
Who is the CEO of Nabsys?
Barrett Bready is listed as CEO at Nabsys.
Where is Nabsys headquartered?
Nabsys is based in Providence, Rhode Island, United States.
How many employees does Nabsys have?
Nabsys is in the 11-50 employee band.
How does Nabsys' funding compare to other Biotechnology startups?
Nabsys' latest round of $13.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Nabsys Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Nabsys is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.